CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Cretostimogene grenadenorepvec

Our lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically-delivered immunotherapy. In BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) it has shown promise in delivering effective therapy with an adverse event rate that is consistent with other intravesical therapies.
Learn More

CG Oncology by the Numbers

Based on preliminary clinical data presented at SUO annual meeting 2023, Phase 3 BOND-003 study of cretostimogene grenadenorepvec in monotherapy for patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC):

with other studies planned. See current clinical trials.

%

of patients evaluable for efficacy (n=50/66) have achieved complete response (CR) at any time.

%

of patients evaluable for efficacy (n=42/66) have achieved complete response (CR) at the 6-month landmark assessment.

The adverse event profile of cretostimogene grenadenorepvec as monotherapy is consistent with that observed in prior studies. The most common treatment-related adverse events reported include transient grade 1-2 local genitourinary symptoms. No grade 3 or higher adverse events related to cretostimogene grenadenorepvec were observed.

Latest News

More press releases